Global Rhinitis Market, By Types (Allergic, Non-Allergic, Others), Treatment (Antihistamines, Decongestants, Corticosteroid, Anticholinergic, Immunotherapy, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Rhinitis Market Analysis and Size
The global angina pectoris drugs market is expected to witness significant growth during the forecast period. Due to increased environmental irritants or air pollution, upper respiratory infections, drug-drug interaction, overuse of nasal decongestant sprays and presence of disease conditions such as GERD, asthma, chronic sinusitis and deviated septum, will boost up the rhinitis market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global rhinitis market in the forecast period 2022-2029. The expected CAGR of global rhinitis market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 12.64 billion in 2021, and it would grow upto USD 17.30 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Rhinitis is the inflammation and swelling of mucous membrane lining of the nose. The epithelial lining contains hairs that produce mucus to trap dust & dirt, to filter the incoming air, and contain sensory receptors that trigger the sneeze reflex to expel any irritants. When the lining inflamed and irritated, it triggers symptoms in the nose and surrounding structures such as rhinorrhea (runny nose), and sneezing among others.
Rhinitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Allergic, Non-Allergic, Others), Treatment (Antihistamines, Decongestants, Corticosteroid, Anticholinergic, Immunotherapy, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Mitsubishi Chemical Group Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), AstraZeneca (U.K.), Genentech, Inc (U.S.)
|
|
Market Opportunities
|
|
Global Rhinitis Market Dynamics
Drivers
- Increasing Prevalence of Rhinitis
The prevalence of rhinitis, both allergic and non-allergic are on the rise. The prevalence of allergic rhinitis ranged from as low as 9% to as high as 42% and the prevalence of nonallergic rhinitis appears to be very common with an estimated prevalence in the U.S. of approximately 19 million. This boost the market growth.
- Strategic Collaborations and Acquisitions
Major market players are associating with startups, mergers and acquisitions, joint ventures, and partnership firms to boost the market growth. The players are constantly pushng themselves hard to add new products to their portfolio to remain at the forefront. For instance, US FDA approved Glenmark’s nasal spray to treat allergic rhinitis. Glenmark has collaborated with Menarini for commercialization purposes. This boosts the market growth
Opportunities
- Increasing Demand for Retail Pharmacies
Rise in the number of rhinitis therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Rising Healthcare Expenditure
Since the last few decades, it has been witnessed that global per capita healthcare spending has improved considerably due to rising rate of awareness associated with the availability of treatments and diagnostic methods for treating various diseases. More and more healthcare spending is likely to result in increasing demand for better diagnostic methods, which in turn, create high growth opportunities for market players operating in the treatment of allergic and non-allergic rhinitis in the global rhinitis market.
Restraints/Challenges
- Lack of skilled professionals
The lack of experienced personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global rhinitis market over a forecast period.
- High Cost
The huge expenditure associated with the treatment of angina pectoris surely hamper the market growth.
This global rhinitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global rhinitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Rhinitis Market
The demand for rhinitis drugs is likely to grow with the rising implications of allergic and non-allergic among COVID-19 patients. The number of rhinitis patients entering into the emergency rooms has reduced in the case of COVID-19. COVID-19 patients were given more priority than the non-COVID patients during the pandemic which lowered the market growth. All these factors negatively impacted the market growth but slowly the market is set to rise due to the decrease in COVID-19 patients.
Global Angina Pectoris Drugs Market Scope
The global rhinitis market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Allergic
- Non-Allergic
- Others
Treatment
- Antihistamines
- Decongestants
- Corticosteroid
- Anticholinergic
- Immunotherapy
- Others
Route of Administration
- Oral
- Parenteral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Rhinitis Market Regional Analysis/Insights
The global rhinitis market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global rhinitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global rhinitis market throughout the forecasted period due to greater awareness about this disease & its treatment, and number of generic drugs.
North America dominates the market due to the increased incidence of allergic reactions. Europe anticipates second largest market share due to increased healthcare expenditure
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Rhinitis Market Share Analysis
The global rhinitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global rhinitis market
Key players operating in the global rhinitis market include:
- Pfizer Inc.(U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Lilly (U.S.)
- Teva Pharmaceutical Industries (Israel)
- Mitsubishi Chemical Group Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- AstraZeneca (U.K.)
- Genentech, Inc (U.S.)
SKU-